Mirtazapina Stada (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Stada, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients. It works by modulating neurotransmitter activity to improve mood and alleviate depressive symptoms.

GNH USA supplies Mirtazapina Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, quality assurance and regulatory support for global distribution and timely delivery.

Mirtazapine is used within the antidepressant therapeutic class to address mood disorders.

Major depressive disorder: reduces depressive symptoms and improves overall mood. Depressive episodes in bipolar disorder: helps stabilize mood during depressive phases. Anxiety associated with depression (off‑label): may lessen anxiety symptoms in patients with comorbid depression.

Mirtazapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness or light‑headedness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Suicidal thoughts or behavior, especially early in treatment - Severe hypotension or syncope - Hepatic dysfunction or jaundice - Allergic reactions such as rash or angioedema

Before prescribing Mirtazapina Stada, clinicians should consider several safety aspects.

Assess hepatic function: evaluate liver enzymes prior to initiation. Monitor weight: watch for rapid weight gain and metabolic changes. Screen for suicidal ideation: especially during the first weeks of therapy. Use caution in elderly patients: increased risk of falls and sedation. Avoid abrupt discontinuation: taper the dose under medical supervision. Store at ambient temperature: keep in the original container, protect from moisture and light.

Mirtazapina Stada can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Strong CYP3A4 inducers (e.g., carbamazepine, rifampicin): may reduce mirtazapine exposure. - Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels.

Moderate Interactions (Monitor Closely): - Alcohol and other CNS depressants: additive sedation. - Other serotonergic agents (e.g., SSRIs, SNRIs): monitor for serotonin excess. - Warfarin: may affect INR, require closer monitoring. - Antihistamines: may enhance anticholinergic effects.